More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence (NICE).

The drug will now be available to people with early-stage non small cell lung cancer (NSCLC) who have had surgery to remove their tumour that has errors in a gene called EGFR.

An immunotherapy combination could be better than standard ‘Extreme’ chemotherapy as first-line treatment for some patients with relapsed or metastatic head and neck cancer, or both, a major phase III trial suggests.

A protein involved in making cells move offers a clue to how certain types of cancer metastasize and develop into secondary tumors, according to new research from the University of Warwick.